Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−4.567 CHF
−443.06 M CHF
6.34 M CHF
113.56 M
About Cytokinetics, Incorporated
Sector
CEO
Robert I. Blum
Headquarters
South San Francisco
Website
Founded
1997
FIGI
BBG00LVD6PZ0
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
CYTK5615147
Cytokinetics, Incorporated 3.5% 01-JUL-2027Yield to maturity
−4.22%
Maturity date
Jul 1, 2027
CYTK4910847
Cytokinetics, Incorporated 4.0% 15-NOV-2026Yield to maturity
−22.31%
Maturity date
Nov 15, 2026
Explore more bonds
Frequently Asked Questions
The current price of KK3A is 46.987 CHF — it has decreased by −17.10% in the past 24 hours. Watch CYTOKINETICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange CYTOKINETICS INC stocks are traded under the ticker KK3A.
KK3A stock hasn't changed in a week, the last month showed zero change in price, over the last year CYTOKINETICS INC has showed a 59.17% increase.
We've gathered analysts' opinions on CYTOKINETICS INC future price: according to them, KK3A price has a max estimate of 107.16 CHF and a min estimate of 53.58 CHF. Watch KK3A chart and read a more detailed CYTOKINETICS INC stock forecast: see what analysts think of CYTOKINETICS INC and suggest that you do with its stocks.
KK3A reached its all-time high on Jan 10, 2024 with the price of 85.736 CHF, and its all-time low was 29.520 CHF and was reached on Nov 13, 2023. View more price dynamics on KK3A chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KK3A stock is 20.63% volatile and has beta coefficient of 0.78. Track CYTOKINETICS INC stock price on the chart and check out the list of the most volatile stocks — is CYTOKINETICS INC there?
Today CYTOKINETICS INC has the market capitalization of 5.19 B, it has increased by 0.91% over the last week.
Yes, you can track CYTOKINETICS INC financials in yearly and quarterly reports right on TradingView.
CYTOKINETICS INC is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
KK3A earnings for the last quarter are −1.15 CHF per share, whereas the estimation was −1.05 CHF resulting in a −10.16% surprise. The estimated earnings for the next quarter are −1.09 CHF per share. See more details about CYTOKINETICS INC earnings.
CYTOKINETICS INC revenue for the last quarter amounts to 392.36 K CHF, despite the estimated figure of 1.03 M CHF. In the next quarter, revenue is expected to reach 1.76 M CHF.
KK3A net income for the last quarter is −136.05 M CHF, while the quarter before that showed −128.85 M CHF of net income which accounts for −5.59% change. Track more CYTOKINETICS INC financial stats to get the full picture.
No, KK3A doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 423.00 employees. See our rating of the largest employees — is CYTOKINETICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CYTOKINETICS INC EBITDA is −433.16 M CHF, and current EBITDA margin is −6.43 K%. See more stats in CYTOKINETICS INC financial statements.
Like other stocks, KK3A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYTOKINETICS INC stock right from TradingView charts — choose your broker and connect to your account.